On April 6, 2009, the Chinese Government announced its ambitious health care reform plan. The reform aims to build a Basic Health Care System by 2020 that will provide affordable health care services to all Chinese population.
The Chinese Government has committed significant funding to the reform, including $125 billion from 2009 to 2011. The reform will bring new opportunities and challenges to pharmaceutical, biologics and medical device companies doing business in China.
In this turbulent political context, this Sept. 9 webinar will carefully analyze areas of potential risk for manufacturers and address important questions such as:
- How will reform reshape China’s health care system for pharmaceutical and medical devices companies?
- Which products will benefit most from China health care reform?
- How will China’s National Essential Drug List be implemented and how will it impact multinational pharmaceutical companies?
- How will health care reforms affect pricing for drugs and devices in China?
- What adjustments will companies need to make to ensure compliance with a reshaped health care regulatory regime?
Get the inside scoop live from Beijing on this exclusive webinar! Get your questions answered without ever leaving your office. Join us Sept. 9 at 3 pm CET/2 pm WET.
To register, visit: http://www.windhover.com/ezine/html/ac0909-2lp.htm
